JP2007521312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521312A5 JP2007521312A5 JP2006520138A JP2006520138A JP2007521312A5 JP 2007521312 A5 JP2007521312 A5 JP 2007521312A5 JP 2006520138 A JP2006520138 A JP 2006520138A JP 2006520138 A JP2006520138 A JP 2006520138A JP 2007521312 A5 JP2007521312 A5 JP 2007521312A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- amino
- dione
- pyrrole
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 2-methylthioethyl Chemical group 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 33
- 238000011282 treatment Methods 0.000 claims 15
- 230000002265 prevention Effects 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 5
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000033227 intestinal cholesterol absorption Effects 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- YQQHQHXKODBEOZ-UHFFFAOYSA-N 1-(2-methoxyethyl)-3-(4-methylsulfanylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(SC)C=C1 YQQHQHXKODBEOZ-UHFFFAOYSA-N 0.000 claims 1
- YARVSNLAHFZJKN-UHFFFAOYSA-N 1-(2-methoxyethyl)-3-(4-morpholin-4-ylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC(C=C1)=CC=C1N1CCOCC1 YARVSNLAHFZJKN-UHFFFAOYSA-N 0.000 claims 1
- YDUSKSCVRROBON-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=COC=C1 YDUSKSCVRROBON-UHFFFAOYSA-N 0.000 claims 1
- NMRHBQAKGYVFQZ-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=C(N)N=C1 NMRHBQAKGYVFQZ-UHFFFAOYSA-N 0.000 claims 1
- JDHWLVUZCIEPGC-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-(4-morpholin-4-ylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=NC(N)=CC=C1CN1C(=O)C(C=2C=CC=CC=2)=C(NC=2C=CC(=CC=2)N2CCOCC2)C1=O JDHWLVUZCIEPGC-UHFFFAOYSA-N 0.000 claims 1
- XPAWGAHBNJTADB-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(difluoromethoxy)anilino]-4-phenylpyrrole-2,5-dione Chemical compound C1=NC(N)=CC=C1CN1C(=O)C(C=2C=CC=CC=2)=C(NC=2C=CC(OC(F)F)=CC=2)C1=O XPAWGAHBNJTADB-UHFFFAOYSA-N 0.000 claims 1
- CUEFJLIVXWUITG-UHFFFAOYSA-N 1-[[4-(dimethylamino)phenyl]methyl]-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=C(N(C)C)C=C1 CUEFJLIVXWUITG-UHFFFAOYSA-N 0.000 claims 1
- IJDRKXJGEDBBKZ-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(OC)C=C1 IJDRKXJGEDBBKZ-UHFFFAOYSA-N 0.000 claims 1
- VWDGCBRPFUNZBZ-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(2-methylsulfanylethyl)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CCSC)C1=O VWDGCBRPFUNZBZ-UHFFFAOYSA-N 0.000 claims 1
- LGKWEWTVEPDUAV-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(3-methoxypropyl)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCCOC)C(=O)C=1NC1=CC=C(OC)C=C1 LGKWEWTVEPDUAV-UHFFFAOYSA-N 0.000 claims 1
- YMJWBXIXSZYSHH-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-[(5-methyl-1,2-oxazol-3-yl)methyl]-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=NOC(C)=C1 YMJWBXIXSZYSHH-UHFFFAOYSA-N 0.000 claims 1
- OYBLWUWJHPWMTA-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CC(F)(F)F)C1=O OYBLWUWJHPWMTA-UHFFFAOYSA-N 0.000 claims 1
- PIAPWUIDIJHWFZ-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(3,3,3-trifluoropropyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CCC(F)(F)F)C1=O PIAPWUIDIJHWFZ-UHFFFAOYSA-N 0.000 claims 1
- WMNVVLNVJBKEMR-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-2-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CC=N1 WMNVVLNVJBKEMR-UHFFFAOYSA-N 0.000 claims 1
- UUADKLHVJWMDLF-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 UUADKLHVJWMDLF-UHFFFAOYSA-N 0.000 claims 1
- BWABNEHKDRQBPP-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-4-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=NC=C1 BWABNEHKDRQBPP-UHFFFAOYSA-N 0.000 claims 1
- CGAORHFPTNYUGA-UHFFFAOYSA-N 3-(4-morpholin-4-ylanilino)-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound O=C1C(C=2C=CC=CC=2)=C(NC=2C=CC(=CC=2)N2CCOCC2)C(=O)N1CC1=CC=CN=C1 CGAORHFPTNYUGA-UHFFFAOYSA-N 0.000 claims 1
- RPTBJJNNXVXBKM-UHFFFAOYSA-N 3-[(2-acetyl-1-benzofuran-5-yl)amino]-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dione Chemical compound O=C1N(CCOC)C(=O)C(NC=2C=C3C=C(OC3=CC=2)C(C)=O)=C1C1=CC=CC=C1 RPTBJJNNXVXBKM-UHFFFAOYSA-N 0.000 claims 1
- QNMXSSQGJHJCLI-UHFFFAOYSA-N 3-[(2-acetyl-1-benzofuran-5-yl)amino]-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C=1C=C2OC(C(=O)C)=CC2=CC=1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 QNMXSSQGJHJCLI-UHFFFAOYSA-N 0.000 claims 1
- GRBPWTWSVBRHIQ-UHFFFAOYSA-N 3-[4-(difluoromethoxy)anilino]-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(OC(F)F)C=C1 GRBPWTWSVBRHIQ-UHFFFAOYSA-N 0.000 claims 1
- DIGLAFAKZCPPOA-UHFFFAOYSA-N 3-[4-(difluoromethoxy)anilino]-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC(F)F)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 DIGLAFAKZCPPOA-UHFFFAOYSA-N 0.000 claims 1
- RAQFUEVZUPBBNT-UHFFFAOYSA-N 3-anilino-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound O=C1C(C=2C=CC=CC=2)=C(NC=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 RAQFUEVZUPBBNT-UHFFFAOYSA-N 0.000 claims 1
- DGYFPKIMHGNRES-UHFFFAOYSA-N 3-phenyl-1-(2,2,2-trifluoroethyl)-4-[4-(trifluoromethoxy)anilino]pyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CC(F)(F)F)C(=O)C=1NC1=CC=C(OC(F)(F)F)C=C1 DGYFPKIMHGNRES-UHFFFAOYSA-N 0.000 claims 1
- NGJSBKOSAZGTJL-UHFFFAOYSA-N 3-phenyl-1-(pyridin-3-ylmethyl)-4-[4-(trifluoromethoxy)anilino]pyrrole-2,5-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 NGJSBKOSAZGTJL-UHFFFAOYSA-N 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- FBPNLPUTIKFOLV-UHFFFAOYSA-N n-[4-[[1-(2-methoxyethyl)-2,5-dioxo-4-phenylpyrrol-3-yl]amino]phenyl]acetamide Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(NC(C)=O)C=C1 FBPNLPUTIKFOLV-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004141 reverse cholesterol transport Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 0 *C(C(C(N1*)=O)N)C1=O Chemical compound *C(C(C(N1*)=O)N)C1=O 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316232.8A GB0316232D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
| PCT/SE2004/001114 WO2005005417A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521312A JP2007521312A (ja) | 2007-08-02 |
| JP2007521312A5 true JP2007521312A5 (enExample) | 2007-09-13 |
Family
ID=27741983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520138A Withdrawn JP2007521312A (ja) | 2003-07-11 | 2004-07-08 | 肝ｘ受容体調節薬としてのピロール−２，５−ジオン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7432288B2 (enExample) |
| EP (1) | EP1646626B1 (enExample) |
| JP (1) | JP2007521312A (enExample) |
| KR (1) | KR20060035748A (enExample) |
| CN (1) | CN1823061A (enExample) |
| AR (1) | AR045721A1 (enExample) |
| AT (1) | ATE399777T1 (enExample) |
| AU (1) | AU2004255999B2 (enExample) |
| BR (1) | BRPI0412472A (enExample) |
| CA (1) | CA2532056A1 (enExample) |
| DE (1) | DE602004014773D1 (enExample) |
| ES (1) | ES2308204T3 (enExample) |
| GB (1) | GB0316232D0 (enExample) |
| IL (1) | IL172760A0 (enExample) |
| IS (1) | IS8293A (enExample) |
| MX (1) | MXPA06000414A (enExample) |
| MY (1) | MY135821A (enExample) |
| NO (1) | NO20060081L (enExample) |
| RU (1) | RU2006102130A (enExample) |
| SA (1) | SA04250204B1 (enExample) |
| TW (1) | TW200503691A (enExample) |
| UA (1) | UA82109C2 (enExample) |
| UY (1) | UY28408A1 (enExample) |
| WO (1) | WO2005005417A1 (enExample) |
| ZA (1) | ZA200600222B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE513823T1 (de) * | 2004-08-17 | 2011-07-15 | Simpson Biotech Co Ltd | Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung |
| US7505238B2 (en) * | 2005-01-07 | 2009-03-17 | Agnes Neves Woo | ESD configuration for low parasitic capacitance I/O |
| US7582629B2 (en) | 2005-01-10 | 2009-09-01 | Astrazeneca Ab | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| MX2008013477A (es) * | 2006-04-28 | 2008-10-29 | Esteve Labor Dr | Compuestos biciclicos de tetrahidropirrol. |
| EP2069359B1 (en) | 2006-08-21 | 2014-11-12 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| PE20110570A1 (es) | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
| CA2727252A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Isoindolone derivatives as mek kinase inhibitors and methods of use |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| AU2011336970A1 (en) | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
| EP2646018B1 (en) | 2010-12-03 | 2014-10-22 | Allergan, Inc. | Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CN109069461A (zh) | 2016-01-11 | 2018-12-21 | 洛克菲勒大学 | 与髓源性抑制细胞相关的病症的治疗方法 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| US11753374B2 (en) * | 2020-11-18 | 2023-09-12 | Southern Reserach Institute | Compounds for the treatment of acute and chronic kidney disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4929999A (en) | 1998-07-30 | 2000-02-21 | Japan Tobacco Inc. | Disubstituted maleimide compounds and medicinal utilization thereof |
| DE69922526T2 (de) * | 1998-10-08 | 2005-06-02 | Smithkline Beecham Plc, Brentford | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| CA2377999A1 (en) * | 1999-07-08 | 2001-01-18 | Tularik Inc | Compositions and methods for raising hdl cholesterol levels |
| WO2001013916A1 (en) | 1999-08-20 | 2001-03-01 | Sagami Chemical Research Center | Drugs inhibiting cell death |
| GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
-
2003
- 2003-07-11 GB GBGB0316232.8A patent/GB0316232D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119064A patent/TW200503691A/zh unknown
- 2004-07-05 SA SA4250204A patent/SA04250204B1/ar unknown
- 2004-07-08 CN CNA2004800198411A patent/CN1823061A/zh active Pending
- 2004-07-08 WO PCT/SE2004/001114 patent/WO2005005417A1/en not_active Ceased
- 2004-07-08 ES ES04749150T patent/ES2308204T3/es not_active Expired - Lifetime
- 2004-07-08 US US10/564,235 patent/US7432288B2/en not_active Expired - Fee Related
- 2004-07-08 DE DE602004014773T patent/DE602004014773D1/de not_active Expired - Fee Related
- 2004-07-08 JP JP2006520138A patent/JP2007521312A/ja not_active Withdrawn
- 2004-07-08 MX MXPA06000414A patent/MXPA06000414A/es not_active Application Discontinuation
- 2004-07-08 BR BRPI0412472-3A patent/BRPI0412472A/pt not_active IP Right Cessation
- 2004-07-08 CA CA002532056A patent/CA2532056A1/en not_active Abandoned
- 2004-07-08 AT AT04749150T patent/ATE399777T1/de not_active IP Right Cessation
- 2004-07-08 AR ARP040102419A patent/AR045721A1/es not_active Application Discontinuation
- 2004-07-08 EP EP04749150A patent/EP1646626B1/en not_active Expired - Lifetime
- 2004-07-08 AU AU2004255999A patent/AU2004255999B2/en not_active Ceased
- 2004-07-08 RU RU2006102130/04A patent/RU2006102130A/ru not_active Application Discontinuation
- 2004-07-08 KR KR1020067000712A patent/KR20060035748A/ko not_active Withdrawn
- 2004-07-09 UY UY28408A patent/UY28408A1/es unknown
- 2004-07-09 MY MYPI20042745A patent/MY135821A/en unknown
- 2004-08-07 UA UAA200600272A patent/UA82109C2/uk unknown
-
2005
- 2005-12-22 IL IL172760A patent/IL172760A0/en unknown
-
2006
- 2006-01-05 NO NO20060081A patent/NO20060081L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600222A patent/ZA200600222B/en unknown
- 2006-02-09 IS IS8293A patent/IS8293A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521312A5 (enExample) | ||
| CN110023302B (zh) | 用作dhodh抑制剂的2,4,5-三取代的1,2,4-三唑酮 | |
| JP2005526723A5 (enExample) | ||
| JP2010518026A5 (enExample) | ||
| JP2011515462A5 (enExample) | ||
| RU2006102130A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| JP2005530722A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| CN1152870A (zh) | 杂环化合物作为多巴胺d3配位体的用途 | |
| JP2007519754A5 (enExample) | ||
| TW201840549A (zh) | 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺 | |
| CN107709301B (zh) | 吡唑衍生物或其药理学上可接受的盐 | |
| CN101611013A (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| EA007720B1 (ru) | Производные триазола в качестве антагонистов рецептора тахикинина | |
| CN102395567A (zh) | 在治疗糖尿病和肥胖症中用作的tgr5激动剂的三唑和咪唑衍生物 | |
| JP2005508923A5 (enExample) | ||
| JP2007521313A5 (enExample) | ||
| JP2004524279A5 (enExample) | ||
| JPWO2021170109A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| RU2006102129A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| WO2018210729A1 (en) | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor | |
| JP7416757B2 (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| JP2004525183A5 (enExample) | ||
| JP2009501745A5 (enExample) |